We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CM Life Sciences III Inc | NASDAQ:CMLT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.69 | 8.49 | 8.88 | 0 | 01:00:00 |
| | Important Notice Regarding the Availability of Proxy Materials for the 2022 Annual Meeting of Stockholders to be Held on September 30, 2022 at 8:00 a.m., Eastern Time via a live audio webcast at www.virtualshareholdermeeting.com/EQRX2022 | | |
| | YOUR VOTE IS IMPORTANT. You are cordially invited to attend the meeting online. Whether or not you plan to attend the Annual Meeting, we urge you to submit your vote via the internet, telephone or mail as soon as possible to ensure your shares are represented. For additional instructions on voting by telephone or the internet, please refer to your Notice of Internet Availability of Proxy Materials or proxy card that may be mailed to you. Returning the proxy does not deprive you of your right to attend the Annual Meeting and to vote your shares at the Annual Meeting. | | |
| | Internet proxy voting may be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. | | |
|
Name
|
| |
Positions and Offices Held
with EQRx |
| |
Director
Since |
| |
Age
|
| ||||||
| Paul Berns | | | Class I Director | | | | | 2021 | | | | | | 55 | | |
| Jorge Conde | | | Class I Director | | | | | 2021 | | | | | | 45 | | |
| Sandra Horning | | | Class I Director | | | | | 2021 | | | | | | 73 | | |
|
Name
|
| |
Positions and Offices Held with
EQRx |
| |
Director
Since |
| |
Class and Year
in Which Term Will Expire |
| |
Age
|
| ||||||
| Kathryn Giusti | | | Director | | | | | 2021 | | | |
Class II - 2023
|
| | | | 63 | | |
| Clive Meanwell, M.D., Ph.D. | | | Director | | | | | 2021 | | | |
Class II - 2023
|
| | | | 65 | | |
| Samuel Merksamer | | | Director | | | | | 2021 | | | |
Class II - 2023
|
| | | | 42 | | |
| Krishna Yeshwant, M.D. | | | Director | | | | | 2021 | | | |
Class II - 2023
|
| | | | 44 | | |
| Amy Abernethy, M.D., Ph.D. | | | Director | | | | | 2021 | | | |
Class III - 2024
|
| | | | 53 | | |
| Alexis Borisy | | | Executive Chairman | | | | | 2021 | | | |
Class III - 2024
|
| | | | 50 | | |
| Eli Casdin | | | Director | | | | | 2021 | | | |
Class III - 2024
|
| | | | 49 | | |
| Melanie Nallicheri | | |
President, Chief Executive Officer and
Director
|
| | | | 2021 | | | |
Class III - 2024
|
| | | | 54 | | |
|
Name
|
| |
Fees
Earned or Paid-in Cash ($) |
| |
Option
Awards(1)(4) ($) |
| |
All Other
Compensation(2) ($) |
| |
Total
($) |
| ||||||||||||
| Amy Abernethy | | | | | 2,344 | | | | | | — | | | | | | — | | | | | | 2,344 | | |
| Paul Berns | | | | | 2,853 | | | | | | — | | | | | | — | | | | | | 2,853 | | |
| Eli Casdin | | | | | 3,057 | | | | | | — | | | | | | — | | | | | | 3,057 | | |
| Jorge Conde(3) | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| Kathy Giusti | | | | | 11,698 | | | | | | 799,806 | | | | | | — | | | | | | 811,504 | | |
| Sandra Horning | | | | | 50,917 | | | | | | — | | | | | | 100,000 | | | | | | 150,917 | | |
| Clive Meanwell | | | | | 50,510 | | | | | | — | | | | | | — | | | | | | 50,510 | | |
| Samuel Merksamer | | | | | 2,446 | | | | | | — | | | | | | — | | | | | | 2,446 | | |
| Krishna Yeshwant | | | | | 2,955 | | | | | | — | | | | | | — | | | | | | 2,955 | | |
|
Name
|
| |
Options
Outstanding at 2021 Fiscal Year End |
| |||
| Kathy Giusti | | | | | 159,286 | | |
| Sandra Horning | | | | | 313,500 | | |
| Clive Meanwell | | | | | 313,500 | | |
|
Fee Category
|
| |
Year ended
December 31, 2021 |
| |
Year ended
December 31, 2020 |
| ||||||
| Audit fees(1) | | | | $ | 1,675,000 | | | | | $ | 250,258 | | |
| Tax fees(2) | | | | | 288,064 | | | | | | 9,670 | | |
| All other Fees | | | | | — | | | | | | — | | |
|
Total
|
| | | $ | 1,963,064 | | | | | $ | 259,928 | | |
|
Name of Beneficial Owner
|
| |
Number of
shares |
| |
% of
common stock |
| ||||||
| Directors and named executive officers | | | | | | | | | | | | | |
| Melanie Nallicheri(1) | | | | | 10,487,335 | | | | | | 2.1% | | |
| Jami Rubin(2) | | | | | 2,291,175 | | | | | | * | | |
| Eric Hedrick(3) | | | | | 773,761 | | | | | | * | | |
| Alexis Borisy(4) | | | | | 19,404,399 | | | | | | 4.0% | | |
| Amy Abernethy | | | | | 200,000 | | | | | | * | | |
| Paul Berns | | | | | 627,000 | | | | | | * | | |
| Eli Casdin(5)(6) | | | | | 56,297,042 | | | | | | 11.3% | | |
| Jorge Conde | | | | | — | | | |
—
|
| |||
| Kathryn Giusti(7) | | | | | 53,094 | | | | | | * | | |
| Sandra Horning(8) | | | | | 627,002 | | | | | | * | | |
| Clive Meanwell(9) | | | | | 137,158 | | | | | | * | | |
| Samuel Merksamer | | | | | — | | | |
—
|
| |||
| Krishna Yeshwant(10) | | | | | — | | | |
—
|
| |||
|
All executive officers and directors as a group (14 individuals)
|
| | | | 91,138,510 | | | | | | 18.3% | | |
| 5% beneficial owners | | | | | | | | | | | | | |
| Entities affiliated with Casdin Partners(5) | | | | | 39,527,669 | | | | | | 8.1% | | |
| Entities affiliated with ARCH Venture Partners(11) | | | | | 36,335,375 | | | | | | 7.4% | | |
| Entities affiliated with Softbank(12) | | | | | 43,976,600 | | | | | | 9.0% | | |
| Entities affiliated with GV 2019, L.P.(13) | | | | | 47,252,687 | | | | | | 9.7% | | |
| Entities affiliated with Andreessen Horowitz(14) | | | | | 53,064,157 | | | | | | 10.9% | | |
|
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights (#) |
| |
Weighted-
average exercise price of outstanding options, warrants and rights ($) |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in the first column) |
| |||||||||
|
Equity compensation plans approved by security
holders(1) |
| | | | 21,624,447 | | | | | | 3.39 | | | | | | 59,353,357 | | |
| Equity compensation plans not approved by security holders | | | | | — | | | | | | — | | | | | | — | | |
|
Total
|
| | | | 21,624,447 | | | | | | | | | | | | 59,353,357 | | |
|
Name
|
| |
Position Held with EQRx
|
| |
Age
|
| |||
| Dina Ciarimboli | | | General Counsel and Secretary | | | | | 53 | | |
| Eric Hedrick, M.D. | | | Chief Physician Executive | | | | | 57 | | |
| Jami Rubin | | | Chief Financial Officer | | | | | 59 | | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Stock
Awards(1) ($) |
| |
Non-Equity
Incentive Plan Compensation(2) ($) |
| |
All Other
Compensation(3) ($) |
| |
Total
($) |
| |||||||||||||||||||||
Alexis Borisy(4)
Executive Chairman and Former Chief Executive Officer |
| | | | 2021 | | | | | | 514,667 | | | | | | — | | | | | | 3,446,560 | | | | | | 343,555 | | | | | | — | | | | | | 4,304,782 | | |
| | | 2020 | | | | | | 575,000 | | | | | | — | | | | | | — | | | | | | 396,750 | | | | | | — | | | | | | 971,750 | | | ||
Melanie Nallicheri(5)
President and Chief Executive Officer |
| | | | 2021 | | | | | | 509,333 | | | | | | — | | | | | | 2,778,121 | | | | | | 311,071 | | | | | | 11,600 | | | | | | 3,610,125 | | |
| | | 2020 | | | | | | 475,000 | | | | | | — | | | | | | — | | | | | | 285,000 | | | | | | 11,400 | | | | | | 771,400 | | | ||
Jami Rubin(6)
Chief Financial Officer |
| | | | 2021 | | | | | | 304,394 | | | | | | — | | | | | | 3,605,355 | | | | | | 175,173 | | | | | | | | | | | | 4,084,922 | | |
| | | 2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Eric Hedrick, M.D.(7)
Chief Physician Executive |
| | | | 2021 | | | | | | 405,000 | | | | | | — | | | | | | 161,773 | | | | | | 170,100 | | | | | | — | | | | | | 736,873 | | |
| | | 2020 | | | | | | 146,250 | | | | | | — | | | | | | — | | | | | | 61,032 | | | | | | — | | | | | | 207,282 | | |
|
Name
|
| |
2021
Base Salary ($) |
| |||
| Alexis Borisy | | | | | 360,000(1) | | |
| Melanie Nallicheri | | | | | 550,000(2) | | |
| Jami Rubin | | | | | 410,000 | | |
| Eric Hedrick | | | | | 405,000 | | |
|
Name
|
| |
2021
Bonus Target (%) |
| |||
| Alexis Borisy | | | | | 55.0(1) | | |
| Melanie Nallicheri | | | | | 55.0(1) | | |
| Jami Rubin | | | | | 40.0 | | |
| Eric Hedrick | | | | | 35.0 | | |
| | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(3) |
| |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(3) |
| |||||||||||||||||||||||||||
Alexis Borisy | | | | | 137,157 | | | | | | 2,057,342 | | | | | | — | | | | | | 2.68(1) | | | | | | 6/6/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | 8,327,326(4) | | | | | | 56,792,363 | | | | | | — | | | | | | — | | |
Melanie Nallicheri | | | | | — | | | | | | 626,999 | | | | | | — | | | | | | 2.21(2) | | | | | | 1/20/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 78,375 | | | | | | 1,175,624 | | | | | | — | | | | | | 2.68(1) | | | | | | 6/6/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,747,297(4) | | | | | | 25,556,566 | | | | | | — | | | | | | — | | | | |||||
| | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | — | | | | | | 555,150(4) | | | | | | 3,786,123 | | |
Jami Rubin | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | — | | | | | | 940,500(5) | | | | | | 6,414,210 | | |
| | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | — | | | | | | 627,000(6) | | | | | | 4,276,140 | | |
Eric Hedrick | | | | | — | | | | | | 175,873 | | | | | | — | | | | | | 2.21(2) | | | | | | 1/20/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | — | | | | | | 417,998(7) | | | | | | 2,850,746 | | |
1 Year CM Life Sciences III Chart |
1 Month CM Life Sciences III Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions